LAWRENCE, Mass., Nov. 7, 2013 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported third quarter financial results with total revenue within its guidance range.
Revenue for the third quarter of 2013 increased 9% to a record $66.9 million, compared with revenue of $61.2 million for the third quarter of 2012. The higher revenues were driven by increased adoption of the NxStage® System One™.
Home revenue increased 5.5% to $33.7 million for the third quarter of 2013 compared with revenue of $31.9 million for the third quarter of 2012. The Company's domestic home revenue for the third quarter of 2013 increased 8.1% over the prior year period, driving all of Home's annual and sequential growth, and offsetting lower international revenue compared with the prior year.
Critical Care revenue increased to $10.7 million for the third quarter of 2013 compared with revenue of $9.1 million for the third quarter of 2012. In-center revenue increased to $21.3 million for the third quarter of 2013 compared with revenue of $19.6 million for the third quarter of 2012.
NxStage reported a net loss of $5.0 million, or $(0.08) per share for the third quarter of 2013 compared with a net loss of $2.6 million, or $(0.04) per share for the third quarter of 2012.
"We continue to make solid progress in strategic areas that are focused on accelerating growth over the longer term," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage. "We're seeing good momentum in the domestic market and believe our growth opportunity here remains very robust. In addition to our direct to patient marketing initiatives, we have a significant opportunity to improve our patients' experiences and increase adoption of our therapies with both our innovative product pipeline and our centers of excellence. These initiatives remain solidly on track and we believe they are positioning the Company toward our goal of 15% annual home revenue growth in 2014 and beyond."
Separately, the Company announced that the U.S. Food and Drug Administration (FDA) cleared the Company's Nx2me Connected Health™ solution. Nx2me Connected Health provides new features and capabilities that are important to home dialysis patients and nurses, including tools that automate a significant part of flow sheet administrative paperwork. With this clearance, the Company expects to begin offering Nx2me in the US later this year.
For the fourth quarter of 2013, the Company is forecasting revenues to be between $67.0 million and $68.5 million, and a net loss in the range of $6.0 to $5.0 million, or ($0.10) to ($0.08) per share.
This translates to full-year 2013 revenue to be within a range of $261.0 to $262.5 million and a net loss in the range of $19.5 to $18.5 million, or ($0.32) to ($0.31) per share, compared with the Company's previous guidance for full-year 2013 revenue to be a range of $265 to $270 million and a net loss in the range of $17 to $13 million, or ($0.28) to ($0.22) per share. The Company's revised net loss for the full-year 2013 includes continued investment in the Company's strategic growth initiatives, including centers of excellence.
The components of the Company's revised full-year 2013 revenue guidance include Home at 6.5% to 7.5%, Critical Care at approximately 10%, and In-Center at 6% to 7% annual growth. The Company's guidance for $4 million in sales to Asahi remains unchanged for the full-year 2013.
"The net change to our year end revenue guidance reflects a longer ramp of international revenue growth and lower growth in critical care disposable sales compared with our earlier projections," stated Matthew W. Towse, Chief Financial Officer. "We remain committed to the investments that we believe will drive growth in 2014 and beyond."
Conference Call:NxStage will also host a conference call today, Thursday, November 7, 2013 at 9:00 a.m. Eastern Time to discuss its third quarter financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international). The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at www.nxstage.com.
A replay of the conference call will be available 2 hours after the completion of the call through November 15, 2013. To access the replay, dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 76263079. An online archive of the conference call can be accessed via the investor relations section of the Company's website at www.nxstage.com.
About the NxStage System OneThe NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the FDA. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow™ SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation, and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products domestically and internationally, growth in home and/or more frequent hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and more frequent hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Healthcare Partners Inc. and Fresenius Medical Care, including in response to NxStage's new centers of excellence initiative, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2013.
In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.
Kristen K. Sheppard, Esq.
VP, Investor Relations
Non-GAAP Financial Measure
The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA adjusted for stock based-compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses) to understand operational cash usage. The Company believes the non-GAAP financial measure provides useful and supplementary information allowing investors greater transparency to one measure used by management. The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial measures. The non-GAAP financial measure is reconciled to the most comparable GAAP financial measure below.NxStage Medical, Inc.Condensed Consolidated Statements of Comprehensive Loss(in thousands, except per share data)(unaudited)Three Months Ended September 30,Nine Months Ended September 30,2013201220132012Revenues
177,112Cost of revenues
25,52823,74874,61567,449Operating expenses:Selling and marketing
12,37410,16834,78630,006Research and development
5,3264,73115,27113,845General and administrative
7,7916,92123,85420,473Total operating expenses
29,94126,09487,83576,745Loss from operations
(4,413)(2,346)(13,220)(9,296)Other expense:Interest expense
(162)(26)(462)(2,675)Other (expense) income, net
(142)13(328)(118)(304)(13)(790)(2,793)Net loss before income taxes
(4,717)(2,359)(14,010)(12,089)Provision for (benefit from) income taxes
(12,789)Net loss per share, basic and diluted
(0.22)Weighted-average shares outstanding, basic and diluted
60,67558,94560,02957,482Other comprehensive income (loss)
257711(302)587Total comprehensive loss
NxStage Medical, Inc.Condensed Consolidated Balance Sheets(in thousands, except share data)(unaudited)September 30,December 31,20132012ASSETSCurrent assets:Cash and cash equivalents
106,439Accounts receivable, net
37,09733,504Prepaid expenses and other current assets
5,0242,534Total current assets
147,803161,467Property and equipment, net
47,10636,320Field equipment, net
13,67010,101Deferred cost of revenues
33,69238,028Intangible assets, net
311,949LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable
18,16020,400Other current liabilities
2,5162,187Total current liabilities
52,36159,262Other long-term liabilities
109,511114,358Commitments and contingenciesStockholders' equity:Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no
shares issued and outstanding as of September 30, 2013 and December 31, 2012
——Common stock: par value $0.001, 100,000,000 shares authorized; 61,333,363 and
59,850,117 shares issued as of September 30, 2013 and December 31, 2012,
6159Additional paid-in capital
(358,366)(344,981)Accumulated other comprehensive income
168470Treasury stock, at cost: 575,895 and 541,584 shares as of September 30, 2013
and December 31, 2012, respectively
(9,963)(9,551)Total stockholders' equity
195,091197,591Total liabilities and stockholders' equity
NxStage Medical, Inc.Cash Flows from Operating Activities(in thousands)(unaudited)Nine Months Ended September 30,20132012Cash flows from operating activities:Net loss
(12,789)Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Depreciation and amortization
2,2513,047Changes in operating assets and liabilities:Accounts receivable
(14,498)(11,638)Prepaid expenses and other assets
49(863)Accrued expenses and other liabilities
(5,707)(3,449)Net cash (used in) provided by operating activities
NxStage Medical, Inc.Revenues by Segment(in thousands)(unaudited)Three Months Ended September 30,Nine Months Ended September 30,2013201220132012System One segmentHome
10,6719,09932,20728,257Total System One segment
NxStage Medical, Inc.Non-GAAP Financial Measures(in millions)(unaudited)Three Months Ended September 30,Nine Months Ended September 30,2013201220132012Net loss
(12.8)Less: Depreciation, amortization, interest, and taxes
22.214.171.1241.0Less: Adjusting items*
5.9* Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses
|SOURCE NxStage Medical, Inc.|
Copyright©2012 PR Newswire.
All rights reserved